These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 23112960)

  • 21. Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice.
    Warimwe GM; Lorenzo G; Lopez-Gil E; Reyes-Sandoval A; Cottingham MG; Spencer AJ; Collins KA; Dicks MD; Milicic A; Lall A; Furze J; Turner AV; Hill AV; Brun A; Gilbert SC
    Virol J; 2013 Dec; 10():349. PubMed ID: 24304565
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Attenuation and protective efficacy of Rift Valley fever phlebovirus rMP12-GM50 strain.
    Ly HJ; Nishiyama S; Lokugamage N; Smith JK; Zhang L; Perez D; Juelich TL; Freiberg AN; Ikegami T
    Vaccine; 2017 Dec; 35(48 Pt B):6634-6642. PubMed ID: 29061350
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A single immunization with MVA expressing GnGc glycoproteins promotes epitope-specific CD8+-T cell activation and protects immune-competent mice against a lethal RVFV infection.
    López-Gil E; Lorenzo G; Hevia E; Borrego B; Eiden M; Groschup M; Gilbert SC; Brun A
    PLoS Negl Trop Dis; 2013; 7(7):e2309. PubMed ID: 23875044
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccination of alpacas against Rift Valley fever virus: Safety, immunogenicity and pathogenicity of MP-12 vaccine.
    Rissmann M; Ulrich R; Schröder C; Hammerschmidt B; Hanke D; Mroz C; Groschup MH; Eiden M
    Vaccine; 2017 Jan; 35(4):655-662. PubMed ID: 28012779
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity of a Candidate Live Attenuated Vaccine for Rift Valley Fever Virus with a Two-Segmented Genome.
    Ayers VB; Huang YS; Dunlop JI; Kohl A; Brennan B; Higgs S; Vanlandingham DL
    Viral Immunol; 2023 Jan; 36(1):33-40. PubMed ID: 36399689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The nonstructural protein NSs induces a variable antibody response in domestic ruminants naturally infected with Rift Valley fever virus.
    Fernandez JC; Billecocq A; Durand JP; Cêtre-Sossah C; Cardinale E; Marianneau P; Pépin M; Tordo N; Bouloy M
    Clin Vaccine Immunol; 2012 Jan; 19(1):5-10. PubMed ID: 22072723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MBT/Pas mouse: a relevant model for the evaluation of Rift Valley fever vaccines.
    Ayari-Fakhfakh E; do Valle TZ; Guillemot L; Panthier JJ; Bouloy M; Ghram A; Albina E; Cêtre-Sossah C
    J Gen Virol; 2012 Jul; 93(Pt 7):1456-1464. PubMed ID: 22513390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single-dose immunization with virus replicon particles confers rapid robust protection against Rift Valley fever virus challenge.
    Dodd KA; Bird BH; Metcalfe MG; Nichol ST; Albariño CG
    J Virol; 2012 Apr; 86(8):4204-12. PubMed ID: 22345465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rift Valley fever virus: A review of diagnosis and vaccination, and implications for emergence in Europe.
    Mansfield KL; Banyard AC; McElhinney L; Johnson N; Horton DL; Hernández-Triana LM; Fooks AR
    Vaccine; 2015 Oct; 33(42):5520-5531. PubMed ID: 26296499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Four-segmented Rift Valley fever virus-based vaccines can be applied safely in ewes during pregnancy.
    Wichgers Schreur PJ; van Keulen L; Kant J; Kortekaas J
    Vaccine; 2017 May; 35(23):3123-3128. PubMed ID: 28457675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing gn protects mice against Rift Valley fever virus.
    Bhardwaj N; Heise MT; Ross TM
    PLoS Negl Trop Dis; 2010 Jun; 4(6):e725. PubMed ID: 20582312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rift Valley Fever.
    Kimble JB; Noronha L; Trujillo JD; Mitzel D; Richt JA; Wilson WC
    Vet Clin North Am Food Anim Pract; 2024 Jul; 40(2):293-304. PubMed ID: 38453549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rift Valley fever vaccines: current and future needs.
    Dungu B; Lubisi BA; Ikegami T
    Curr Opin Virol; 2018 Apr; 29():8-15. PubMed ID: 29514112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response of laboratory staff to vaccination with an inactivated Rift Valley fever vaccine--TSI-GSD 200.
    Frank-Peterside N
    Afr J Med Med Sci; 2000 Jun; 29(2):89-92. PubMed ID: 11379456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk analysis of inter-species reassortment through a Rift Valley fever phlebovirus MP-12 vaccine strain.
    Ly HJ; Lokugamage N; Nishiyama S; Ikegami T
    PLoS One; 2017; 12(9):e0185194. PubMed ID: 28926632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of veterinary vaccines for prevention and control of Rift Valley fever: memorandum from a WHO/FAO meeting.
    Bull World Health Organ; 1983; 61(2):261-8. PubMed ID: 6602663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine.
    Botros B; Omar A; Elian K; Mohamed G; Soliman A; Salib A; Salman D; Saad M; Earhart K
    J Med Virol; 2006 Jun; 78(6):787-91. PubMed ID: 16628582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathological studies on postvaccinal reactions of Rift Valley fever in goats.
    Kamal SA
    Virol J; 2009 Jul; 6():94. PubMed ID: 19580675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. One Health approach to Rift Valley fever vaccine development.
    Kortekaas J
    Antiviral Res; 2014 Jun; 106():24-32. PubMed ID: 24681125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a novel, single-cycle replicable rift valley Fever vaccine.
    Murakami S; Terasaki K; Ramirez SI; Morrill JC; Makino S
    PLoS Negl Trop Dis; 2014 Mar; 8(3):e2746. PubMed ID: 24651859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.